- Home
- ABSI vs PGEN Comparison
ABSI vs PGEN Comparison
Compare ABSI & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- PGEN
- Stock Information
- Founded
- ABSI 2011
- PGEN 1998
- Country
- ABSI United States
- PGEN United States
- Employees
- ABSI N/A
- PGEN N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- PGEN Health Care
- Exchange
- ABSI Nasdaq
- PGEN Nasdaq
- Market Cap
- ABSI 353.8M
- PGEN 344.0M
- IPO Year
- ABSI 2021
- PGEN N/A
- Fundamental
- Price
- ABSI $3.09
- PGEN $1.39
- Analyst Decision
- ABSI Strong Buy
- PGEN Strong Buy
- Analyst Count
- ABSI 5
- PGEN 4
- Target Price
- ABSI $8.40
- PGEN $7.33
- AVG Volume (30 Days)
- ABSI 3.4M
- PGEN 1.5M
- Earning Date
- ABSI 05-13-2025
- PGEN 05-13-2025
- Dividend Yield
- ABSI N/A
- PGEN N/A
- EPS Growth
- ABSI N/A
- PGEN N/A
- EPS
- ABSI N/A
- PGEN N/A
- Revenue
- ABSI $4,534,000.00
- PGEN $3,925,000.00
- Revenue This Year
- ABSI $156.33
- PGEN $318.39
- Revenue Next Year
- ABSI $93.61
- PGEN $789.17
- P/E Ratio
- ABSI N/A
- PGEN N/A
- Revenue Growth
- ABSI N/A
- PGEN N/A
- 52 Week Low
- ABSI $2.01
- PGEN $0.65
- 52 Week High
- ABSI $6.33
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- ABSI 54.32
- PGEN 44.92
- Support Level
- ABSI $2.95
- PGEN $1.12
- Resistance Level
- ABSI $3.30
- PGEN $1.49
- Average True Range (ATR)
- ABSI 0.28
- PGEN 0.14
- MACD
- ABSI 0.12
- PGEN 0.00
- Stochastic Oscillator
- ABSI 83.85
- PGEN 63.64
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.